Corcept Therapeutics Inc CORT Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$110.16 down $3.21, 2.83% at close Oct 16
Last close · Previous close $113.37
- Market cap
- At the Oct 16 close
- P/E ratio
- 262.29On last 12 months’ EPS
- Diluted EPS
- $0.42Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$110.16down $3.21, 2.83%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$113.37Oct 15
- Volume849.97KOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.60MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $28.66 to $126.38; now $110.16
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CORT beat the S&P 500 in 6 of 7 periods.
| Period | CORT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CORT: down 1.5% S&P 500: up 1.5% | CORT trailed the S&P 500 by 3.0 percentage points Trailed |
| 3M | CORT: up 22.8% S&P 500: up 1.9% | CORT beat the S&P 500 by 20.9 percentage points Beat |
| YTD | CORT: up 216.6% S&P 500: up 12.8% | CORT beat the S&P 500 by 203.8 percentage points Beat |
| 1Y | CORT: up 38.6% S&P 500: up 16.8% | CORT beat the S&P 500 by 21.8 percentage points Beat |
| Long term | ||
| 3Y | CORT: up 292.2% S&P 500: up 81.5% +57.7% vs +22.0% a year | CORT beat the S&P 500 by 210.7 percentage points Beat |
| 5Y | CORT: up 449.7% S&P 500: up 83.1% +40.6% vs +12.9% a year | CORT beat the S&P 500 by 366.6 percentage points Beat |
| 10Y | CORT: up 1,659.7% S&P 500: up 319.6% +33.2% vs +15.4% a year | CORT beat the S&P 500 by 1,340.1 percentage points Beat |
$10,000 invested in CORT 10 years ago (Oct 14, 2016) would be worth about $175,974 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
CORT beat the S&P 500 in 6 of 7 periods.
| Period | CORT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CORT: down 1.5% S&P 500: up 1.2% | CORT trailed the S&P 500 by 2.7 percentage points Trailed |
| 3M | CORT: up 22.8% S&P 500: up 1.7% | CORT beat the S&P 500 by 21.1 percentage points Beat |
| YTD | CORT: up 216.6% S&P 500: up 11.9% | CORT beat the S&P 500 by 204.7 percentage points Beat |
| 1Y | CORT: up 38.6% S&P 500: up 15.5% | CORT beat the S&P 500 by 23.1 percentage points Beat |
| Long term | ||
| 3Y | CORT: up 292.2% S&P 500: up 75.0% +57.7% vs +20.5% a year | CORT beat the S&P 500 by 217.2 percentage points Beat |
| 5Y | CORT: up 449.7% S&P 500: up 71.2% +40.6% vs +11.4% a year | CORT beat the S&P 500 by 378.5 percentage points Beat |
| 10Y | CORT: up 1,659.7% S&P 500: up 258.1% +33.2% vs +13.6% a year | CORT beat the S&P 500 by 1,401.6 percentage points Beat |
$10,000 invested in CORT 10 years ago (Oct 14, 2016) would be worth about $175,974 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$123.57
Closing high on . Now 10.9% below that record.
Split-adjusted daily closes since Apr 14, 2004.
Stock splits
CORT hasn’t split since its price history begins in 2004.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $830.81Mup 16.0%
- Net income
- $54.20Mdown 58.9%
- Diluted EPS
- $0.42down 62.5%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $182.55M | $46.69M | $0.41 |
| Q4 FY24 (Dec 31, 2024) | $181.89M | $30.39M | $0.25 |
| Q1 FY25 (Mar 31, 2025) | $157.21M | $20.29M | $0.17 |
| Q2 FY25 (Jun 30, 2025) | $194.43M | $34.61M | $0.29 |
| Q3 FY25 (Sep 30, 2025) | $207.64M | $19.36M | $0.16 |
| Q4 FY25 (Dec 31, 2025) | $202.13M | $23.90M | $0.20 |
| Q1 FY26 (Mar 31, 2026) | $164.90M | −$31.20M | −$0.30 |
| Q2 FY26 (Jun 30, 2026) | $256.15M | $42.14M | $0.36 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $365.98M | $112.51M | $0.89 |
| FY22 (Dec 31, 2022) | $401.86M | $101.29M | $0.87 |
| FY23 (Dec 31, 2023) | $482.38M | $105.50M | $0.94 |
| FY24 (Dec 31, 2024) | $675.04M | $139.73M | $1.23 |
| FY25 (Dec 31, 2025) | $761.41M | $98.17M | $0.82 |
Margins
- Gross 98.3%
- Operating 0.8%
- Net 6.5%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $106.92MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$109.70MLast 12 months
- Capital spending$2.78MLast 12 months
- 12.9%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $78.91MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$78.91MLast 12 months
74% of free cash flow
Balance sheet
- $544.65MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$9.42MAs of Jun 30, 2026
- Net cash$535.23MAs of Jun 30, 2026
- 2.86As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.01As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 8.3%Last 12 months
Over the last 12 months, Corcept Therapeutics’s net income was 8.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 6.4%Last 12 months
Over the last 12 months, Corcept Therapeutics’s net income was 6.4% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Corcept Therapeutics Inc
For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CORT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CORT stock FAQ
What is CORT stock’s price today?
Corcept Therapeutics (CORT) traded at $110.16 at the close on , down $3.21 (2.83%) from the previous close of $113.37. Over the past 52 weeks it has traded between $28.66 and $126.38.
If you invested $1,000 in CORT 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CORT on would be worth about $17,597 at the close on , a total return of +1,659.7%. The same $1,000 would be worth $5,497 if invested five years ago, $1,386 if invested one year ago, and $154,937 if invested 20 years ago. Past performance doesn’t predict future returns.
What is CORT’s P/E ratio?
CORT trades at 262.3 times its diluted earnings over the four quarters to ($0.42 per share), at the close. (How the P/E ratio works.)
How much revenue does Corcept Therapeutics make?
Corcept Therapeutics reported $830.8 million of revenue over the four quarters to , up 16.0% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $256.1 million, up 31.7% from a year earlier.
Is Corcept Therapeutics profitable?
Yes. Corcept Therapeutics earned $54.2 million of net income over the four quarters to , a net margin of 6.5%, and its operating margin was 0.8% (what margins tell you).
What are CORT’s earnings per share?
CORT’s diluted earnings per share were $0.42 over the four quarters to , compared with $1.12 in the twelve months before. The latest quarter (Q2 FY26) brought $0.36 per share, against $0.29 a year earlier (how EPS works).
Does CORT pay a dividend?
Corcept Therapeutics hasn’t paid a dividend in the last twelve months.
What is CORT’s 52-week high and low?
Over the past 52 weeks CORT has traded as low as $28.66 and as high as $126.38. At $110.16 at the close on , it is 12.8% below that high and 284.4% above the low.
What is CORT’s all-time high?
CORT’s highest closing price was $123.57 on , adjusted for stock splits. At $110.16 at the close on , it is 10.9% below that record.
Has CORT stock ever split?
No. CORT hasn’t split since its price history begins in 2004.
How has CORT stock performed?
Including dividends and measured to the close on , CORT has returned +216.6% so far this year and +38.6% over the past year, and +449.7% over five years (+40.6% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Corcept Therapeutics in?
Corcept Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does CORT trade on?
Corcept Therapeutics trades on the Nasdaq under the ticker symbol CORT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.